GLP Research · R-GLP 3
R-GLP 3 (10mg)
from $129.00
Mechanism of Action
Research GLP-3 compound for advanced glucagon-like peptide receptor pathway studies.
Research Vectors
- Advanced GLP
- Receptor research
- Metabolic
* Fulfillment subject to stock availability
For research purposes only.This compound is intended strictly for in-vitro laboratory research conducted by qualified professionals. It is not a drug, supplement, cosmetic, or food. It is not intended for use in or on humans or animals and has not been evaluated by the FDA for any purpose.
GLP-1 / GIP / GCG Agonist · 10mg
Retatrutide Protocol Reference Protocol
Triple agonist, once-weekly subcutaneous injection. Appetite regulation support.
BAC Water Reconstitution
Dilution volume: Add 2 mL BAC water to a 10 mg vial.
Quick-Draw Equivalents:
10 Units0.10 mL = 0.5 mg
20 Units0.20 mL = 1.0 mg
40 Units0.40 mL = 2.0 mg
Timing & Administration
☀️ Morning
Most people prefer morning or daytime. Appetite suppression may affect sleep if dosed at night.
🌙 Night
Generally not recommended - appetite suppression can disrupt sleep quality.
Titration Schedule Guide
Some clinical protocols start as low as 0.5-1 mg weekly. Titrate slowly to minimize gastrointestinal effects.
| Phase | Dose | Draw Volume | Protocol Notes |
|---|---|---|---|
| Weeks 1-4 | 1.0-2.0 mg weekly | 20-40 Units | Starting range. Titrate slowly. Use lower end (1 mg) if sensitive to GI side effects. |
| Weeks 5-8 | 4.0 mg weekly | 80 Units | 0.40 mL per injection. Increase only if prior dose is well tolerated for full 4 weeks. |
| Advanced | 6.0-8.0 mg weekly | 120-160 Units | Side effects increase significantly. Clinical supervision strongly advised. |
Cycle Protocol
Increase dosage slowly. Hold each dose level for a full 4 weeks before increasing.
Observed Side Effects
NauseaDiarrheaVomitingDecreased appetiteIncreased heart rateFatigue
Safety Notice: Seek medical advice for severe nausea, dehydration, abdominal pain, vomiting, or signs of pancreatitis.